BRPI0410634A - processo - Google Patents

processo

Info

Publication number
BRPI0410634A
BRPI0410634A BRPI0410634-2A BRPI0410634A BRPI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A
Authority
BR
Brazil
Prior art keywords
genes
gene
gene set
nonresponders
responders
Prior art date
Application number
BRPI0410634-2A
Other languages
English (en)
Inventor
Takashi Tsuruo
Yusuke Nakamura
Saburo Sone
Masahiro Fukuoka
Original Assignee
Astrazeneca Uk Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312451A external-priority patent/GB0312451D0/en
Priority claimed from GB0322636A external-priority patent/GB0322636D0/en
Priority claimed from GB0327132A external-priority patent/GB0327132D0/en
Application filed by Astrazeneca Uk Ltd, Univ Tokyo filed Critical Astrazeneca Uk Ltd
Publication of BRPI0410634A publication Critical patent/BRPI0410634A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PROCESSO". A invenção diz respeito a um conjunto de genes marcadores isolados que compreende pelo menos um gene identificado com expressão diferencial entre pacientes que são respondedores e não respondedores a um inibidor do receptor tirosina quinase erbB; o dito conjunto de genes compreendendo um ou mais genes selecionados pelo menos do grupo que consiste dos (51) genes listados anexos incluindo oligonucleotídeos específicos do gene derivado dos ditos genes; e usos de tais conjuntos em aplicações de diagnóstico.
BRPI0410634-2A 2003-05-30 2004-06-01 processo BRPI0410634A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312451A GB0312451D0 (en) 2003-05-30 2003-05-30 Process
GB0322636A GB0322636D0 (en) 2003-09-26 2003-09-26 Process
GB0327132A GB0327132D0 (en) 2003-11-21 2003-11-21 Process
PCT/GB2004/002316 WO2005049829A1 (en) 2003-05-30 2004-06-01 Process

Publications (1)

Publication Number Publication Date
BRPI0410634A true BRPI0410634A (pt) 2006-06-13

Family

ID=34623472

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410634-2A BRPI0410634A (pt) 2003-05-30 2004-06-01 processo

Country Status (12)

Country Link
US (1) US20060252056A1 (pt)
EP (2) EP2348110B1 (pt)
JP (2) JP4724657B2 (pt)
KR (1) KR101126560B1 (pt)
AU (1) AU2004291709C1 (pt)
BR (1) BRPI0410634A (pt)
CA (1) CA2527680A1 (pt)
IL (1) IL172029A (pt)
MX (1) MXPA05012939A (pt)
NO (1) NO20055459L (pt)
NZ (1) NZ543234A (pt)
WO (1) WO2005049829A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4724657B2 (ja) * 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド プロセス
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
JP2009505658A (ja) 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
FI121236B (fi) * 2006-01-18 2010-08-31 Licentia Oy Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi
US8138167B2 (en) 2006-02-10 2012-03-20 Oncotherapy Science, Inc. Methods for treating lung cancers
JPWO2007099852A1 (ja) * 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
US8288112B2 (en) 2006-04-25 2012-10-16 P&M Venge Ab Protein, an antibody and measurement of the protein
TW200817680A (en) 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
EP2097754B2 (en) * 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
CA2671399A1 (en) * 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
EP2155877A2 (en) * 2007-05-11 2010-02-24 Santaris Pharma A/S Rna antagonist compounds for the modulation of her3
JP2010535523A (ja) * 2007-08-14 2010-11-25 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒインヒビター処理のための予測マーカー
WO2009021679A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treamtent
CA2695473C (en) * 2007-08-14 2013-10-01 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
BRPI0815414A2 (pt) * 2007-08-14 2015-02-03 Hoffmann La Roche Marcador para o tratamento com inibidor de egfr
KR20100037641A (ko) * 2007-08-14 2010-04-09 에프. 호프만-라 로슈 아게 Ｅｇｆｒ 저해제 처리에 대한 예측성 마커
AU2008286407A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive markers for EGFR inhibitor treatment
WO2009021675A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
MX2010001582A (es) * 2007-08-14 2010-06-02 Hoffmann La Roche Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
ES2437122T3 (es) * 2007-08-14 2014-01-09 F. Hoffmann-La Roche Ag Marcador predictivo en el tratamiento inhibidor del EGFR
CA2695250A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015535A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
GB0904957D0 (en) * 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
EP2239578A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)
US20120095030A1 (en) * 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
EP3066474B1 (en) 2013-11-05 2019-04-03 Agency For Science, Technology And Research Bladder carcinoma biomarkers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
IL135622A0 (en) 1997-11-06 2001-05-20 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
RS50081B (sr) 1998-04-29 2009-01-22 Osi Pharmaceuticals I.N.C., N-(3-etinilfenilamino)-6,7-bis (2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
DE69904358T2 (de) 1998-11-19 2003-04-17 Warner-Lambert Co., Morris Plains N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid, ein irreversibler tyrosin-kinasen hemmer
JP2000287680A (ja) * 1999-04-09 2000-10-17 Sentan Kagaku Gijutsu Incubation Center:Kk 未成熟肝細胞を成熟肝細胞へ分化させる方法
EP1192151B1 (en) 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
US7194269B2 (en) 2000-10-30 2007-03-20 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Industry Method and wireless communication hub for data communications
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7332590B2 (en) * 2001-08-16 2008-02-19 The United States Of America As Represented By The Department Of Health And Human Services Molecular characteristics of non-small cell lung cancer
WO2003040317A2 (en) * 2001-11-02 2003-05-15 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
JP2006519620A (ja) * 2003-03-04 2006-08-31 アークチュラス バイオサイエンス，インコーポレイティド 乳がんにおけるｅｒ状態の弁別特性
JP4724657B2 (ja) * 2003-05-30 2011-07-13 アストラゼネカ ユーケー リミテッド プロセス

Also Published As

Publication number Publication date
JP2011167188A (ja) 2011-09-01
EP1633870B1 (en) 2013-03-27
NO20055459L (no) 2006-02-27
MXPA05012939A (es) 2006-05-17
AU2004291709A1 (en) 2005-06-02
NZ543234A (en) 2009-04-30
EP1633870A1 (en) 2006-03-15
AU2004291709B2 (en) 2009-09-10
KR20060002012A (ko) 2006-01-06
KR101126560B1 (ko) 2012-04-05
IL172029A (en) 2011-06-30
JP2006526420A (ja) 2006-11-24
WO2005049829A1 (en) 2005-06-02
JP5217010B2 (ja) 2013-06-19
AU2004291709C1 (en) 2010-03-11
EP2348110B1 (en) 2013-03-27
EP2348110A1 (en) 2011-07-27
US20060252056A1 (en) 2006-11-09
JP4724657B2 (ja) 2011-07-13
NO20055459D0 (no) 2005-11-18
CA2527680A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
BRPI0410634A (pt) processo
DK0759927T3 (da) Pteridinnucleotidanaloger som fluorescerende DNA prober
Mäser et al. Drug transport and drug resistance in African trypanosomes
Winkelman et al. Open complex scrunching before nucleotide addition accounts for the unusual transcription start site of E. coli ribosomal RNA promoters
DE69333073D1 (de) Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
BR9910174A (pt) Processo para se obter um gene recombinante otimizado de resistência à praga, biblioteca, e, processo para se obter um organismo que seja patogênico a uma praga de vegetal
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
BRPI0519959A2 (pt) copolìmero de (met)acrilato aniÈnico parcialmente neutralizado
BR9812650A (pt) ácidos nucléicos hibridizando marcação múltipla, preparação dos mesmos, composições, formulação, kits e aplicações
DE60216798D1 (de) Azyklische linker enthaltende oligonukleotide und deren verwendungen
NO973838D0 (no) DNA-molekyler, deres fremstilling samt anvendelse ved genterapi
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BRPI0414532A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
BR9811006A (pt) Sequência de dna, cassete de expressão, uso do mesmo, processo para transformar uma planta, planta com um elevado teor em vitamina e, processo para gerar plantas com um elevado teor em vitamina e e para gerar plantas com elevada resistência a inibidores de hppd, sistema de teste, subtância herbicamente ativa, uso de uma planta, e, planta com elevada resistência a inibidores de hppd
Nardella et al. DNA methylation bisubstrate inhibitors are fast-acting drugs active against artemisinin-resistant Plasmodium falciparum parasites
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
Peuker et al. α-Cardiac-like myosin heavy chain as an intermediate between MHCIIa and MHCIβ in transforming rabbit muscle
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
DE69815370D1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
BR0303092A (pt) Portfólio para prognóstico de câncer de mama
Lavogina et al. Targeting Plasmodium falciparum protein kinases with adenosine analogue–oligoarginine conjugates

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.